Targets › MYO7A
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Jul 2029.
Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. (UniProt, Q13402)
Open in Phaseline: the race on MYO7A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AAVantgarde Bio Srl | AAVB-081 AAV gene therapy delivering MYO7A cDNA | MYO7A | Phase 1 | Usher Syndrome, Type 1B | Jul 2029 |
Usher Syndrome, Type 1B (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.